Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LARA: Lenvatinib plus Pembrolizumab in Recurrent Gynecological Clear Cell Adenocarcinomas
KCT0007575Phase 2Active, not recruiting
- Sponsor
- Samsung Medical Center
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in clear cell ovarian cancer, clear cell endometrial carcinoma (CCEC), clear cell adenocarcinoma (CCA), sponsored by Samsung Medical Center. Started Dec 2022; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
clear cell ovarian cancerclear cell endometrial carcinoma (CCEC)clear cell adenocarcinoma (CCA)
Beyond the preview
Go deeper on KCT0007575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007575.